The Impact of Pre-Chemotherapy Body Composition and Immunonutritional Markers on Chemotherapy Adherence in Stage III Colorectal Cancer Patients

Patients with colorectal cancer (CRC) often fail to complete full-course chemotherapy with a standard dose due to various reasons. This study aimed to determine whether body composition affects chemotherapy adherence in patients with CRC. The medical records of 107 patients with stage III CRC who underwent adjuvant folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy at a single center between 2014 and 2018 were analyzed retrospectively. Blood test results for selected immunonutritional markers were analyzed and body composition was measured through computed tomography. Univariate and multivariate analyses were performed on low and high relative dose intensity (RDI) groups, based on an RDI of 0.85. In the univariate analysis, a higher skeletal muscle index was correlated with a higher RDI (p = 0.020). Psoas muscle index was also higher in patients with high RDI than in those with low RDI (p = 0.026). Fat indices were independent of RDI. Multivariate analysis was performed for the aforementioned factors and results showed that age (p = 0.028), white blood cell count (p = 0.024), and skeletal muscle index (p = 0.025) affected RDI. In patients with stage III CRC treated with adjuvant FOLFOX chemotherapy, a decrease in RDI was related to age, white blood cell count, and skeletal muscle index. Therefore, if we adjust the drug dosage in consideration of these factors, we can expect an increased treatment efficiency in patients by increasing chemotherapy compliance.

[1]  P. Calder,et al.  Impact of enteral immunonutrition on infectious complications and immune and inflammatory markers in cancer patients undergoing chemotherapy: A systematic review of randomised controlled trials. , 2022, Clinical nutrition.

[2]  J. Meyerhardt,et al.  The association of abdominal adiposity with premature discontinuation of postoperative chemotherapy in colon cancer. , 2022, Clinical nutrition.

[3]  G. Chaves,et al.  Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma , 2021, Acta oncologica.

[4]  Su-Jin Shin,et al.  Impact of subcutaneous and visceral fat adiposity in patients with colorectal cancer. , 2021, Clinical nutrition.

[5]  E. Oki,et al.  Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  N. Suciu,et al.  Psoas Muscle Index Defined by Computer Tomography Predicts the Presence of Postoperative Complications in Colorectal Cancer Surgery , 2021, Medicina.

[7]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[8]  R. Xu,et al.  Novel Genetic and Epigenetic Biomarkers of Prognostic and Predictive Significance in Stage II/III Colorectal Cancer. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Sooyoung Cho,et al.  Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial , 2020, Scientific Reports.

[10]  M. Irwin,et al.  Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer , 2020, Breast Cancer Research and Treatment.

[11]  Daping Fan,et al.  The Acute Effects of 5 Fluorouracil on Skeletal Muscle Resident and Infiltrating Immune Cells in Mice , 2020, Frontiers in Physiology.

[12]  J. Ijzermans,et al.  Prognostic Significance of the Controlling Nutritional Status (CONUT) Score in Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis. , 2020, International journal of surgery.

[13]  C. Gross,et al.  Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumors , 2020, Cancer.

[14]  C. Prado,et al.  Nutrition interventions to treat low muscle mass in cancer , 2020, Journal of cachexia, sarcopenia and muscle.

[15]  B. Caan,et al.  Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer. , 2019, JAMA oncology.

[16]  A. Forgione,et al.  Compliance to Adjuvant Chemotherapy of Patients Who Underwent Surgery for Rectal Cancer: Report from a Multi-institutional Research Network , 2019, World Journal of Surgery.

[17]  J. Meyerhardt,et al.  The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I–III colorectal cancer: a population‐based cohort study (C‐SCANS) , 2018, Journal of cachexia, sarcopenia and muscle.

[18]  J. Meyerhardt,et al.  Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C‐SCANS study , 2017, Cancer.

[19]  J. Meyerhardt,et al.  Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study , 2017, JAMA oncology.

[20]  Z. Pan,et al.  Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer , 2017, Chinese journal of cancer.

[21]  M. Yano,et al.  Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer. , 2017, Anticancer research.

[22]  T. Zimmers,et al.  Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs , 2016, Oncotarget.

[23]  M. Sawyer,et al.  Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens , 2016, Cancer medicine.

[24]  Wenjun Xie,et al.  Excess TGF-β mediates muscle weakness associated with bone metastases in mice , 2015, Nature Medicine.

[25]  Masataka Taguri,et al.  Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. , 2015, Journal of hepatology.

[26]  W. Frontera,et al.  Skeletal Muscle: A Brief Review of Structure and Function , 2015, Calcified Tissue International.

[27]  J. W. Kim,et al.  Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy , 2015, Supportive Care in Cancer.

[28]  L. Bracci,et al.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer , 2013, Cell Death and Differentiation.

[29]  C. Kunisaki,et al.  Impact of body mass index and visceral adiposity on outcomes in colorectal cancer , 2012, Asia-Pacific journal of clinical oncology.

[30]  H. Maas,et al.  Predictors of early death risk in older patients treated with first-line chemotherapy for cancer and the importance of geriatric assessment. , 2012, Journal of Clinical Oncology.

[31]  A. Ravaud,et al.  Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Febbraio,et al.  Muscles, exercise and obesity: skeletal muscle as a secretory organ , 2012, Nature Reviews Endocrinology.

[33]  D. Sargent,et al.  Revised TN categorization for colon cancer based on national survival outcomes data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[35]  G. Kroemer,et al.  Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA , 2004, Oncogene.

[36]  Mark J. Ratain,et al.  Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing , 2001, Investigational New Drugs.

[37]  B. Wajchenberg.  Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. , 2000, Endocrine reviews.

[38]  R. Rosso,et al.  Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy , 1998, Cancer Chemotherapy and Pharmacology.